Closed · DARPA-BAA-12-37 · CFDA 12.910 · Discretionary
Biologically-derived Medicines on Demand (Bio-MOD)
Federal grant opportunity posted by DARPA - Defense Sciences Office, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- June 21, 2012
- Close date
- -
- Expected awards
The verdict
Biologically-derived Medicines on Demand (Bio-MOD) is a closed discretionary listing from DARPA - Defense Sciences Office that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 175 other opportunities from DARPA - Defense Sciences Office.
- Varies
- award range
- Closed
- application status
- 12.910
- CFDA program
- 175
- other opportunities from DARPA - Defense Sciences Office
Archived opportunity record
Biologically-derived Medicines on Demand is closed (last close June 21, 2012). Check the agency catalog for replacement NOFOs. DARPA - Defense Sciences Office still indexes 175 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed June 21, 2012
Instrument
Procurement Contract
Description
The Bio-MOD program seeks to develop devices and techniques to produce multiple protein biologics in response to specific battlefield threats and medical needs. This will be achieved by investing in (1) novel, flexible methodologies for genetic engineering/modification of microbial strains, eukaryotic strains, and/or cell-free systems to synthesize multiple protein-based therapeutics; and (2) flexible and portable device platforms for manufacturing multiple biologics with high purity, efficacy and potency at the point-of-care, in short timeframes, when the specific need arises. Consequently, Bio-MOD will provide a battlefield medical supply for military medics at the front lines of support that is responsive to far-forward emergency settings and emergent in-theater needs.
Catch-all / unrestricted eligibility mark · DARPA-BAA-12-37
Grants.gov marks Biologically-derived Medicines on Demand with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Procurement Contract. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the DARPA - Defense Sciences Office book (96 peers, 55% of 176).
- Code 99
- Unrestricted / see official listing
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
COL Geoffrey Ling
More from DARPA - Defense Sciences Office
What to do next
Biologically-derived Medicines on Demand is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 12.910 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- Compare award ranges across federal categories before you pick a single CFDA. All categories
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |